Santen Pharmaceutical has been granted a patent for an implantable device designed to treat glaucoma. The device includes a flexible tube with a structure extending radially outward in multiple directions, allowing it to divert aqueous humor from the eye’s anterior chamber. The structure is designed to seal to surrounding ocular tissue, preventing leakage of aqueous humor. The device also features a tapered profile to facilitate insertion into the tissue passage. GlobalData’s report on Santen Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Santen Pharmaceutical Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Santen Pharmaceutical, Nanoparticle drug conjugates was a key innovation area identified from patents. Santen Pharmaceutical's grant share as of September 2023 was 38%. Grant share is based on the ratio of number of grants to total number of patents.

Implantable device for glaucoma treatment with aqueous humor drainage